Save 80% on generic Nexavar vs US generic Nexavar.
Information about Nexavar (Sorafenib)
Nexavar is the brand name for sorafenib, a targeted therapy medication used in the treatment of certain types of cancer. It belongs to a class of drugs known as kinase inhibitors, which work by blocking specific enzymes that promote the growth of cancer cells and blood vessels that supply tumors with nutrients. Sorafenib is primarily used to treat liver, kidney, and thyroid cancers.
Product Highlights
Nexavar is used in the treatment of:
It is indicated for the treatment of advanced liver cancer (hepatocellular carcinoma), either alone or in combination with other therapies.
Nexavar is used for the treatment of advanced or metastatic renal cell carcinoma (a type of kidney cancer), typically in patients who have received prior treatment with other therapies.
Nexavar is approved for the treatment of progressive, metastatic differentiated thyroid cancer (DTC) that no longer responds to radioactive iodine therapy.
Nexavar is sometimes studied off-label for other cancers, though it is not officially approved for all these indications.
Key Ingredient
Sorafenib
Key Benefits
Nexavar targets specific molecules involved in cancer cell growth and the formation of blood vessels that supply tumors, helping to slow or stop the progression of certain cancers.
Sorafenib is used in the treatment of liver, kidney, and thyroid cancers, making it a versatile treatment for advanced or metastatic cancers.
Studies have shown that Nexavar can help improve survival rates in patients with advanced hepatocellular carcinoma (liver cancer) and metastatic renal cell carcinoma (kidney cancer).
By inhibiting both tumor cell growth and angiogenesis, Nexavar can slow the progression of cancer and, in some cases, shrink tumors.
Nexavar is taken orally, providing a convenient treatment option compared to intravenous therapies.
Direction of Use
Nexavar is taken as an oral tablet, usually twice a day, about 12 hours apart. The tablets should be taken whole with water and can be ingested with or without food.
The typical dose for adults is 400 mg twice daily (total daily dose of 800 mg), but dosing may vary based on individual patient characteristics and tolerability.
If a dose is missed, take it as soon as possible, unless it is almost time for the next dose. Do not take two doses at once to compensate for a missed dose.
The length of treatment with Nexavar depends on the individual’s response to the drug, side effects, and the progression of the disease.
Recommended Dose Adjustment Guidelines for Patients with Differentiated Thyroid Carcinoma
Dose Level
Total daily dose
Dosage
0
800 mg daily dose
(400 mg twice daily, 2 tablets twice daily)
-1
600 mg daily dose
(400 mg and 200 mg 12 hours apart, 2 tablets and 1 tablet 12 hours apart – either dose can come first)
-2
400 mg daily dose
(200 mg twice daily, 1 tablet twice daily)
-3
200 mg daily dose
(200 mg once daily, one tablet once daily)
Safety Concerns
Common side effects include fatigue, diarrhea, high blood pressure, rash, and hand-foot skin reactions (redness, swelling, and pain on the palms of hands and soles of feet).
Sorafenib can cause high blood pressure (hypertension) and, in rare cases, heart failure or other cardiovascular problems. Regular blood pressure monitoring is recommended.
Sorafenib can affect liver function, potentially leading to liver toxicity or liver failure. Liver enzyme levels should be checked regularly during treatment.
Sorafenib may increase the risk of bleeding, especially in patients with tumors that affect blood vessels. It is important to monitor for signs of bleeding, such as easy bruising, nosebleeds, or blood in stools or urine.
Diarrhea, nausea, and vomiting are common side effects. These should be addressed with the guidance of a healthcare provider.
Many patients experience fatigue, rash, and hand-foot syndrome, which may require dose adjustments or additional treatments to manage symptoms.
Avoid Nexavar (Sorafenib) If
Do not use Nexavar if you have a known allergy to sorafenib or any of the inactive ingredients in the formulation.
Nexavar should not be used in patients with severe liver impairment (Child-Pugh class C), as the drug is metabolized by the liver, and its toxicity may be increased.
Avoid Nexavar in patients with severe cardiovascular conditions, such as uncontrolled hypertension, heart failure, or a history of heart attack, due to the potential for worsening these conditions.
Nexavar is classified as a pregnancy Category D medication, meaning it may harm the fetus. It should only be used during pregnancy if the benefits outweigh the risks. It is also advised against during breastfeeding, as it may be excreted in breast milk.
Avoid use in patients with a history of severe bleeding disorders, as Nexavar increases the risk of bleeding.
